Strategy for the Treatment of Helicobacter pylori Infection

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)


Volume 20, 42 Issues, 2014


Download PDF Flyer




Current Pharmaceutical Design

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 62nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
William A. Banks
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.288
5 - Year: 3.555

Strategy for the Treatment of Helicobacter pylori Infection

Author(s): Seiji Shiota and Yoshio Yamaoka

Affiliation: Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu-City, Oita 879-5593, Japan.

Abstract

The eradication of Helicobacter pylori not only heals peptic ulcers but also prevents their recurrence and reduces the risk of development of gastric cancer and other H. pylori-associated disorders. H. pylori eradication heals gastritis and may prevent the spread of infection, reducing the future costs required for the treatment of subsequent H. pylori-associated diseases. There are various guidelines for the management of H. pylori infection worldwide, such as the guidelines of the American College of Gastroenterology, Maastricht IV, the Second Asia-Pacific Consensus Conference, and Japan. The Japanese health insurance system approved H. pylori eradication therapy for H. pylori-related chronic gastritis in 2013. Triple therapy regimens comprising 1 proton pump inhibitor and 2 antimicrobial agents such as amoxicillin, clarithromycin, metronidazole, levofloxacin, or tetracycline have been widely used to eradicate this bacterium. The rate of successful eradication has declined owing to the increased rate of drug resistance stemming from the wide usage of antibiotics. This issue is of particular relevance with regard to clarithromycin. In worldwide, clarithromycin-based triple therapy should be abandoned, as it is no longer effective. Quadruple therapy and sequential therapy are reasonable alternatives for initial therapy. First-line treatment should be recommended on the basis of an understanding of the local prevalence of H. pylori antimicrobial resistance.

Keywords: Helicobacter pylori, guideline, management, treatment, resistance.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 20
Issue Number: 28
First Page: 4489
Last Page: 4500
Page Count: 12
DOI: 10.2174/13816128113196660731
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science